Literature DB >> 30273194

Age and CD20 Expression Are Significant Prognostic Factors in Human Herpes Virus-8-negative Effusion-based Lymphoma.

Tomomi Kubota1, Yosuke Sasaki2, Eisuke Shiozawa2, Masafumi Takimoto2, Tsunekazu Hishima3, Ja-Mun Chong1.   

Abstract

Human herpes virus-8 (HHV-8)-negative effusion-based lymphoma (HHV-8-negative EBL) can be distinguished from primary effusion lymphoma based on clinical and pathologic findings. Although the morphology between the 2 is similar and they both originate from body cavities with serous effusions and are characterized by lack of tumor masses, HHV-8-negative EBL generally occurs in older patients, and has favorable response to therapy and better prognosis than primary effusion lymphoma. However, no systematic studies have investigated prognostic factors in patients with HHV-8-negative EBL. In this report, clinical and pathologic characteristics of 67 cases of HHV-8-negative EBL, including 2 of our own cases, were analyzed. Univariate analyses revealed older age (70 y and above), Japanese ethnicity, pericardial effusion, CD20 expression, and chemotherapy with rituximab were significantly favorable prognostic factors. Peritoneal effusion was identified as an unfavorable prognostic factor. In the multivariate analysis, age and CD20 expression were independent prognostic factors (P=0.013 and 0.003, respectively). A past history of induced fluid overload, hepatitis C viral infection, and peritoneal effusion were significantly correlated with patients aged below 70 years, while pericardial and pleural effusions were significantly correlated with patients aged 70 years and above. A comparison of cases with and without CD20 expression revealed that Japanese ethnicity and pericardial effusion were significantly correlated with CD20 expression, whereas a past history of induced fluid overload and peritoneal effusion were significantly correlated with the absence of CD20. We concluded that older age and CD20 expression are significant and favorable independent prognostic factors of HHV-8-negative EBL.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30273194     DOI: 10.1097/PAS.0000000000001168

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  5 in total

Review 1.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.

Authors:  Rita Alaggio; Catalina Amador; Ioannis Anagnostopoulos; Ayoma D Attygalle; Iguaracyra Barreto de Oliveira Araujo; Emilio Berti; Govind Bhagat; Anita Maria Borges; Daniel Boyer; Mariarita Calaminici; Amy Chadburn; John K C Chan; Wah Cheuk; Wee-Joo Chng; John K Choi; Shih-Sung Chuang; Sarah E Coupland; Magdalena Czader; Sandeep S Dave; Daphne de Jong; Ming-Qing Du; Kojo S Elenitoba-Johnson; Judith Ferry; Julia Geyer; Dita Gratzinger; Joan Guitart; Sumeet Gujral; Marian Harris; Christine J Harrison; Sylvia Hartmann; Andreas Hochhaus; Patty M Jansen; Kennosuke Karube; Werner Kempf; Joseph Khoury; Hiroshi Kimura; Wolfram Klapper; Alexandra E Kovach; Shaji Kumar; Alexander J Lazar; Stefano Lazzi; Lorenzo Leoncini; Nelson Leung; Vasiliki Leventaki; Xiao-Qiu Li; Megan S Lim; Wei-Ping Liu; Abner Louissaint; Andrea Marcogliese; L Jeffrey Medeiros; Michael Michal; Roberto N Miranda; Christina Mitteldorf; Santiago Montes-Moreno; William Morice; Valentina Nardi; Kikkeri N Naresh; Yasodha Natkunam; Siok-Bian Ng; Ilske Oschlies; German Ott; Marie Parrens; Melissa Pulitzer; S Vincent Rajkumar; Andrew C Rawstron; Karen Rech; Andreas Rosenwald; Jonathan Said; Clémentine Sarkozy; Shahin Sayed; Caner Saygin; Anna Schuh; William Sewell; Reiner Siebert; Aliyah R Sohani; Reuben Tooze; Alexandra Traverse-Glehen; Francisco Vega; Beatrice Vergier; Ashutosh D Wechalekar; Brent Wood; Luc Xerri; Wenbin Xiao
Journal:  Leukemia       Date:  2022-06-22       Impact factor: 12.883

Review 2.  Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics.

Authors:  Savanah D Gisriel; Ji Yuan; Ryan C Braunberger; Danielle L V Maracaja; Xueyan Chen; Xiaojun Wu; Jenna McCracken; Mingyi Chen; Yi Xie; Laura E Brown; Peng Li; Yi Zhou; Tarsheen Sethi; Austin McHenry; Ronald G Hauser; Nathan Paulson; Haiming Tang; Eric D Hsi; Endi Wang; Qian-Yun Zhang; Ken H Young; Mina L Xu; Zenggang Pan
Journal:  Mod Pathol       Date:  2022-05-13       Impact factor: 8.209

Review 3.  Primary Pulmonary B-Cell Lymphoma: A Review and Update.

Authors:  Francesca Sanguedolce; Magda Zanelli; Maurizio Zizzo; Alessandra Bisagni; Alessandra Soriano; Giorgia Cocco; Andrea Palicelli; Giacomo Santandrea; Cecilia Caprera; Matteo Corsi; Giulia Cerrone; Raffaele Sciaccotta; Giovanni Martino; Linda Ricci; Francesco Sollitto; Domenico Loizzi; Stefano Ascani
Journal:  Cancers (Basel)       Date:  2021-01-22       Impact factor: 6.639

4.  Development of a novel cell line-derived xenograft model of primary herpesvirus 8-unrelated effusion large B-cell lymphoma and antitumor activity of birabresib in vitro and in vivo.

Authors:  Tomohiro Nishimori; Tomonori Higuchi; Yumiko Hashida; Takako Ujihara; Ayuko Taniguchi; Fumiya Ogasawara; Naoya Kitamura; Ichiro Murakami; Kensuke Kojima; Masanori Daibata
Journal:  Cancer Med       Date:  2021-11-24       Impact factor: 4.452

5.  Primary age-related EBV-associated effusion-based lymphoma successfully treated with rituximab and thoracentesis.

Authors:  Justin J Kuhlman; Muhamad Alhaj Moustafa; Alexander J Tun; David M Menke; Han W Tun; Liuyan Jiang
Journal:  Clin Case Rep       Date:  2021-04-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.